05). Thirst, pollakiuria were the main observed adverse drug reactions, and thirst could be improved by drinking water. Conclusion: Tolvaptan can effectively increase cirrhosis ascites patients’ 24-hour urine volume, decrease abdominal circumference by administering

15 mg once daily for 5 days, without renal function damage. Also, serum sodium, serum potassium, plasma colloid osmatic pressure can be improved in a steady process. So, it is a great option for those cirrhosis patients accompany with hyponatremia and hepatorenal symdrome. Key Word(s): 1. Tolvaptan; 2. cirrhosis ascites; 3. efficacy; 4. ACP-196 chemical structure safety; Presenting Author: YANJIE CHEN Additional Authors: JIMIN X-396 ZHU, HAO WU, JIA FAN, JIAN ZHOU, JIE HU, QIAN YU, TAOTAO LIU, LEI YANG, CHUNLEI WU, XIAOLING GUO, XIAOWU HUANG, XIZHONG SHEN Corresponding Author: XIAOWU HUANG, XIZHONG SHEN Affiliations: Department of Gastroenterology, Zhongshan Hospital of Fudan University; Liver Cancer Institute, Zhongshan Hospital of Fudan University; Department of Statistics, School of Public Health of Fudan University; Department of Molecular and Experimental Medicine, The Scripps Research Institute Objective: Sensitive and specific detection of liver cirrhosis is an urgent need for

optimal individualized management of disease activity. Substantial studies have identified circulation miRNAs as biomarkers for diverse diseases including chronic liver diseases. In this study, we investigated the plasma miRNA signature

to serve as a potential diagnostic biomarker for silent liver cirrhosis. Methods: A see more genome-wide miRNA microarray was first performed in 80 plasma specimens. Six candidate miRNAs were selected and then trained in CHB-related cirrhosis and controls by qPCR. A classifier, miR-106b and miR-181b, was validated finally in two independent cohort including CHB-related silent cirrhosis and controls, as well as non–CHB-related cirrhosis and controls as validation sets, respectively. Results: A profile of 2 miRNAs (miR-106b and miR-181b) was identified as liver cirrhosis biomarkers irrespective of etiology. The classifier constructed by the two miRNAs provided a high diagnostic accuracy for cirrhosis (AUC = 0.882 for CHB-related cirrhosis in the training set, 0.774 for CHB-related silent cirrhosis in one validation set, and 0.915 for non–CHB-related cirrhosis in another validation set). Conclusion: Our study demonstrated that the combined detection of miR-106b and miR-181b has a considerable clinical value to diagnose patients with liver cirrhosis, especially those at early stage. Key Word(s): 1. biomarker; 2. miR-106b; 3. miR-181b; 4.